All data are based on the daily closing price as of April 10, 2026
h

Hisamitsu Pharmaceutical

4530.TSE
37.97 USD
-0.05
-0.13%

Overview

Last close
37.97 usd
Market cap
2.66B usd
52 week high
41.89 usd
52 week low
25.59 usd
Target price
26.7 usd

Valuation

P/E
22.4213
Forward P/E
12.2699
Price/Sales
2.6595
Price/Book Value
1.5732
Enterprise Value
2.00B usd
EV/Revenue
2.0232
EV/EBITDA
9.6858

Key financials

Revenue TTM
1.00B usd
Gross Profit TTM
590.76M usd
EBITDA TTM
160.14M usd
Earnings per Share
1.69 usd
Dividend
0.55 usd
Total assets
2.19B usd
Net debt
-634.59M usd

About

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.
  • Symbol
    4530.TSE
  • Exchange
    TSE
  • Isin
    JP3784600003
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - Specialty & Generic
  • CEO
    Mr. Kazuhide Nakatomi
  • Headquarter
    Tosu
  • Web site
    https://www.global.hisamitsu
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top